Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5

October 31, 2025 | HighField Bio Press Release

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

The abstract “First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demonstrates Tolerability and Early Clinical Response” discloses new data about HighField’s multi-faceted approach in immunotherapy.
The abstract “Targeting MDSCs with HF1K16 Unlocks Long-term Survival in Refractory Recurrent Glioma; an update of NCT05388487” demonstrates HighField’s vision of developing products that improve overall survival.

HANGZHOU, CHINA, (October 31, 2025) – HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it will make Late Breaking Abstract Presentations on two of its novel immuno-oncology drugs at the Society for Immunotherapy of Cancer (SITC) 40^th Anniversary Meeting November 5 – 9, 2025, in National Harbor, MD.

“We are very encouraged that SITC chose to recognize the significance of our attempts to develop next generation immunotherapies,” said HighField CEO and Scientific Founder Yuhong Xu. “We are leading the development of lipid-based products that focus on the different aspects of T cell modulation in the tumor microenvironment.”

Dr. Xu explained, “HF1K16 and HF50 are part of a pipeline of products derived from our lipid-based therapeutic platforms. They represent a new vision for cancer immunotherapy treatment designed to generate better outcomes for more patients. This pipeline also includes HFG2 based on our platform of TCTplex for T cell gene editing to create in vivo CAR T cells.”

The abstract Number 1314, titled First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demonstrates Tolerability and Early Clinical Response, will be presented Saturday, Nov. 8.

The abstract Number 1350, titled Targeting MDSCs with HF1K16 Unlocks Long-term Survival in Refractory Recurrent Glioma; an update of NCT05388487, will be presented Saturday, Nov. 8.

About HighField Biopharmaceuticals

Highfield is a clinical stage company focused on novel applications of liposome constructs directed to immuno-oncology and gene therapy. HighField’s lead products in clinical trials are K1, derived from its ADCplex^TM platform, followed by HF50, derived from its TCEplex^TMplatform. The company’s pipeline also includes K16, a drug encapsulated immune modulating liposome targeting myeloid-derived suppressor cells in clinical trials for refractory cancers; and HFG1, derived from its tLNPplex™ platform, for mRNA expression of a GLP-1R agonist for weight loss and diabetes. For more information visit highfieldbio.com.

Media Contact:

Dan Eramian

Opus Biotech Communications

danieleramian@comcast.net

425-306-8716

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

The abstract “First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demonstrates Tolerability and Early Clinical Response” discloses new data about HighField’s multi-faceted approach in immunotherapy.

The abstract “Targeting MDSCs with HF1K16 Unlocks Long-term Survival in Refractory Recurrent Glioma; an update of NCT05388487” demonstrates HighField’s vision of developing products that improve overall survival.